FI109540B - Menetelmä terapeuttisesti käyttökelpoisen 40-0-(2-hydroksietyyli) -rapamysiinin valmistamiseksi - Google Patents

Menetelmä terapeuttisesti käyttökelpoisen 40-0-(2-hydroksietyyli) -rapamysiinin valmistamiseksi Download PDF

Info

Publication number
FI109540B
FI109540B FI951678A FI951678A FI109540B FI 109540 B FI109540 B FI 109540B FI 951678 A FI951678 A FI 951678A FI 951678 A FI951678 A FI 951678A FI 109540 B FI109540 B FI 109540B
Authority
FI
Finland
Prior art keywords
rapamycin
alkyl
compound
novel compound
binding
Prior art date
Application number
FI951678A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI951678A (fi
FI951678A0 (fi
Inventor
Sylvain Cottens
Richard Sedrani
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10723188&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI109540(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of FI951678A publication Critical patent/FI951678A/fi
Publication of FI951678A0 publication Critical patent/FI951678A0/fi
Application granted granted Critical
Publication of FI109540B publication Critical patent/FI109540B/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Dental Preparations (AREA)
FI951678A 1992-10-09 1995-04-07 Menetelmä terapeuttisesti käyttökelpoisen 40-0-(2-hydroksietyyli) -rapamysiinin valmistamiseksi FI109540B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9221220 1992-10-09
GB929221220A GB9221220D0 (en) 1992-10-09 1992-10-09 Organic componds
PCT/EP1993/002604 WO1994009010A1 (en) 1992-10-09 1993-09-24 O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants
EP9302604 1993-09-24

Publications (3)

Publication Number Publication Date
FI951678A FI951678A (fi) 1995-04-07
FI951678A0 FI951678A0 (fi) 1995-04-07
FI109540B true FI109540B (fi) 2002-08-30

Family

ID=10723188

Family Applications (2)

Application Number Title Priority Date Filing Date
FI951678A FI109540B (fi) 1992-10-09 1995-04-07 Menetelmä terapeuttisesti käyttökelpoisen 40-0-(2-hydroksietyyli) -rapamysiinin valmistamiseksi
FI20001943A FI20001943A (fi) 1992-10-09 2000-09-04 O-alkyloituja rapamysiinijohdannaisia ja niiden käyttö, erityisesti immunosupressoivina aineina

Family Applications After (1)

Application Number Title Priority Date Filing Date
FI20001943A FI20001943A (fi) 1992-10-09 2000-09-04 O-alkyloituja rapamysiinijohdannaisia ja niiden käyttö, erityisesti immunosupressoivina aineina

Country Status (28)

Country Link
US (2) US5665772A (sk)
EP (3) EP0663916B1 (sk)
JP (2) JP3117462B2 (sk)
KR (2) KR100308598B1 (sk)
AT (2) ATE272063T1 (sk)
AU (1) AU676198B2 (sk)
BR (1) BR1100353A (sk)
CA (2) CA2145383C (sk)
CY (2) CY2125B1 (sk)
CZ (1) CZ283333B6 (sk)
DE (3) DE69322282T2 (sk)
DK (2) DK0867438T3 (sk)
ES (2) ES2124793T3 (sk)
FI (2) FI109540B (sk)
FR (1) FR04C0012I2 (sk)
GB (1) GB9221220D0 (sk)
GE (1) GEP20002331B (sk)
HU (1) HU224074B1 (sk)
LU (1) LU91104I2 (sk)
NL (1) NL300154I2 (sk)
NO (3) NO307053B1 (sk)
NZ (1) NZ256026A (sk)
PL (1) PL176174B1 (sk)
PT (1) PT867438E (sk)
RO (1) RO114451B1 (sk)
RU (1) RU2143434C1 (sk)
SK (2) SK286054B6 (sk)
WO (1) WO1994009010A1 (sk)

Families Citing this family (420)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA935110B (en) * 1992-07-17 1994-02-04 Smithkline Beecham Corp Rapamycin derivatives
ZA935111B (en) * 1992-07-17 1994-02-04 Smithkline Beecham Corp Rapamycin derivatives
USRE40596E1 (en) * 1993-04-08 2008-12-02 Novartis Ag Rapamycin assay
GB9307491D0 (en) 1993-04-08 1993-06-02 Sandoz Ltd Organic compounds
AU686629B2 (en) 1993-04-23 1998-02-12 Wyeth Rapamycin Conjugates and Antibodies
US7279561B1 (en) * 1993-04-23 2007-10-09 Wyeth Anti-rapamycin monoclonal antibodies
USRE37421E1 (en) 1993-07-16 2001-10-23 Smithkline Beecham Corporation Rapamycin derivatives
ES2308955T5 (es) * 1993-09-28 2012-04-03 R.P. Scherer Gmbh Fabricación de cápsulas de gelatina blanda
CA2175215C (en) * 1993-11-19 2008-06-03 Yat Sun Or Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
US5527907A (en) * 1993-11-19 1996-06-18 Abbott Laboratories Macrolide immunomodulators
CN1046944C (zh) * 1993-12-17 1999-12-01 山道士有限公司 雷怕霉素类衍生物
GB9405350D0 (en) * 1994-03-18 1994-05-04 Sandoz Ltd Organic compounds
GB2308546B (en) * 1994-10-26 1999-06-02 Novartis Ag Topical macrolide compositions
IL115742A (en) 1994-10-26 2000-06-01 Novartis Ag Pharmaceutical compositions comprising a difficultly soluble active agent a hydrophilic phase a lipophilic phase and a surfactant
US7205279B2 (en) * 1995-10-25 2007-04-17 Novartis Ag Pharmaceutical compositions
US5561138A (en) * 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
GB9618952D0 (en) * 1996-09-11 1996-10-23 Sandoz Ltd Process
US6187757B1 (en) 1995-06-07 2001-02-13 Ariad Pharmaceuticals, Inc. Regulation of biological events using novel compounds
RU2158267C2 (ru) 1995-06-09 2000-10-27 Новартис Аг Производные рапамицина и фармацевтическая композиция на их основе
BE1009856A5 (fr) * 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
US5780462A (en) * 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
GB9601120D0 (en) * 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
GB9606452D0 (en) 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
KR100616020B1 (ko) * 1996-03-27 2007-01-31 노파르티스 아게 맥관장애및이종이식술에서의라파마이신유도체의용도
ATE222502T1 (de) 1996-07-30 2002-09-15 Novartis Ag Kombinationspräparat mit hemmender wirkung auf die abstossung von transplantaten, autoimmunerkrankungen und entzündungen, welches cyclosporin a und 40-0-(2-hydroxyethyl)-rapamycin enthält
US5922730A (en) * 1996-09-09 1999-07-13 American Home Products Corporation Alkylated rapamycin derivatives
WO1998009970A2 (en) * 1996-09-09 1998-03-12 American Home Products Corporation Alkylated rapamycin derivatives
GB9624038D0 (en) * 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
US6306166B1 (en) * 1997-08-13 2001-10-23 Scimed Life Systems, Inc. Loading and release of water-insoluble drugs
TWI235068B (en) * 1998-03-26 2005-07-01 Fujisawa Pharmaceutical Co Sustained-release pharmaceutical composition
US20050031611A1 (en) * 1998-05-08 2005-02-10 Beth Israel Deaconess Medical Center Transplant tolerance by costimulation blockade and T-cell activation-induced apoptosis
ATE219492T1 (de) * 1998-08-17 2002-07-15 Wyeth Corp Fotocyclisierte rapamycine
US6015809A (en) * 1998-08-17 2000-01-18 American Home Products Corporation Photocyclized rapamycin
GB9826882D0 (en) 1998-12-07 1999-01-27 Novartis Ag Organic compounds
US7276506B2 (en) * 1998-12-28 2007-10-02 4 Aza Bioscience Nv Immunosuppressive effects of pteridine derivatives
US6946465B2 (en) * 1999-02-02 2005-09-20 4 Aza Bioscience Nv Immunosuppressive effects of pteridine derivatives
US7063857B1 (en) 1999-04-30 2006-06-20 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
DE60044717D1 (de) 1999-05-10 2010-09-02 Paolo Brenner Kombination von immunsuppressiven substanzen zur behandlung oder vorbeugung von transplantat abstossungen
US6331547B1 (en) 1999-08-18 2001-12-18 American Home Products Corporation Water soluble SDZ RAD esters
EP1210350B1 (en) * 1999-08-18 2004-07-14 Wyeth Water soluble sdz-rad esters
US7067526B1 (en) 1999-08-24 2006-06-27 Ariad Gene Therapeutics, Inc. 28-epirapalogs
WO2001014387A1 (en) 1999-08-24 2001-03-01 Ariad Gene Therapeutics, Inc. 28-epirapalogs
US20070032853A1 (en) * 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
US6790228B2 (en) 1999-12-23 2004-09-14 Advanced Cardiovascular Systems, Inc. Coating for implantable devices and a method of forming the same
US7807211B2 (en) 1999-09-03 2010-10-05 Advanced Cardiovascular Systems, Inc. Thermal treatment of an implantable medical device
US6277983B1 (en) 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
JP2003519655A (ja) * 2000-01-14 2003-06-24 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア リンパ増殖症候群の緩和および阻害のためのo−メチル化ラパマイシン誘導体
GB0008785D0 (en) 2000-04-10 2000-05-31 Novartis Ag Organic compounds
US8236048B2 (en) 2000-05-12 2012-08-07 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
US6670355B2 (en) 2000-06-16 2003-12-30 Wyeth Method of treating cardiovascular disease
EP1318837B1 (en) 2000-08-11 2004-10-06 Wyeth Method of treating estrogen receptor positive carcinoma
DE60136200D1 (de) 2000-09-19 2008-11-27 Wyeth Corp Wasserlösliche rapamycin-ester
US6399625B1 (en) 2000-09-27 2002-06-04 Wyeth 1-oxorapamycins
MXPA03002871A (es) 2000-09-29 2004-12-06 Johnson & Johnson Dispositivos medicos recubiertos.
US6399626B1 (en) 2000-10-02 2002-06-04 Wyeth Hydroxyesters of 7-desmethylrapamycin
US6440991B1 (en) * 2000-10-02 2002-08-27 Wyeth Ethers of 7-desmethlrapamycin
DE60134679D1 (de) 2000-10-20 2008-08-14 Eisai R&D Man Co Ltd Stickstoff enthaltende aromatische Heterozyklen
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
AU2005201004A1 (en) * 2001-02-19 2005-03-24 Novartis Ag Cancer treatment
AU2016206379B2 (en) * 2001-02-19 2017-09-14 Novartis Ag Cancer Treatment
AU2011226833B9 (en) * 2001-02-19 2014-07-03 Novartis Ag Cancer treatment
ES2728739T3 (es) * 2001-02-19 2019-10-28 Novartis Pharma Ag Derivado de rapamicina para el tratamiento de un tumor sólido asociado con angiogénesis desregulada
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
TWI233359B (en) * 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
EP1406700A1 (en) 2001-07-06 2004-04-14 Sucampo AG Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent
EP1554572B1 (en) 2001-07-25 2009-10-14 Raptor Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
US6939376B2 (en) * 2001-11-05 2005-09-06 Sun Biomedical, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US7682387B2 (en) * 2002-04-24 2010-03-23 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method for treating restenosis
EP1458405A1 (en) * 2001-11-21 2004-09-22 Sucampo AG Use of fk506 and analogues for treating allergic diseases
EP2407473A3 (en) * 2002-02-01 2012-03-21 ARIAD Pharmaceuticals, Inc Method for producing phosphorus-containing compounds
US20030176455A1 (en) * 2002-03-13 2003-09-18 Wyeth Method of inhibiting cell death
US20040024450A1 (en) * 2002-04-24 2004-02-05 Sun Biomedical, Ltd. Drug-delivery endovascular stent and method for treating restenosis
CA2483594C (en) 2002-05-16 2011-02-15 Novartis Ag Use of edg receptor binding agents in cancer
ES2296063T3 (es) 2002-07-16 2008-04-16 Biotica Technology Limited Produccion de poliquetidos y otros productos naturales.
CA2493878C (en) 2002-07-30 2013-07-23 Wyeth Parenteral formulations containing a rapamycin hydroxyester
CA2498191C (en) * 2002-09-18 2012-04-10 Trustees Of The University Of Pennsylvania Method of inhibiting choroidal neovascularization
US20060046979A1 (en) 2002-09-24 2006-03-02 Foster Carolyn A Organic compounds
WO2004060283A2 (en) 2002-12-16 2004-07-22 Nitromed, Inc. Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use
AU2003300076C1 (en) 2002-12-30 2010-03-04 Angiotech International Ag Drug delivery from rapid gelling polymer composition
AR042938A1 (es) * 2003-02-06 2005-07-06 Wyeth Corp Uso del cci-779 en el tratamiento de la fibrosis hepatica
US20090093875A1 (en) 2007-05-01 2009-04-09 Abbott Laboratories Drug eluting stents with prolonged local elution profiles with high local concentrations and low systemic concentrations
AR043504A1 (es) * 2003-03-17 2005-08-03 Novartis Ag Composiciones farmaceuticas que comprenden rapamicina para el tratamiento de enfermedades inflamatorias
GB0307867D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
WO2004089369A2 (en) * 2003-04-11 2004-10-21 Cambridge University Technical Services Limited Methods and means for treating protein conformational disorders
US20040258662A1 (en) * 2003-04-22 2004-12-23 Wyeth Antineoplastic agents
US7160867B2 (en) * 2003-05-16 2007-01-09 Isotechnika, Inc. Rapamycin carbohydrate derivatives
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
PT1646634E (pt) * 2003-07-08 2009-02-16 Novartis Ag Utilização de rapamicina e derivados de rapamicina para o tratamento de perda óssea
AU2004271721A1 (en) * 2003-09-12 2005-03-24 4 Aza Bioscience Nv Pteridine derivatives for the treatment of septic shock and TNF-alpha-related diseases.
CN102144961A (zh) 2003-09-18 2011-08-10 参天制药株式会社 经巩膜递送
US20070032477A1 (en) * 2003-10-17 2007-02-08 Waer Mark J A Pteridine derivatives useful for making pharmaceutical compositions
US7220755B2 (en) * 2003-11-12 2007-05-22 Biosensors International Group, Ltd. 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same
US9114198B2 (en) 2003-11-19 2015-08-25 Advanced Cardiovascular Systems, Inc. Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same
GB0327840D0 (en) * 2003-12-01 2003-12-31 Novartis Ag Organic compounds
ES2315745T3 (es) 2004-03-01 2009-04-01 Terumo Kabushiki Kaisha Procedimiento para la fabricacion de derivados o-alquilados de rapamicina.
JP4716280B2 (ja) * 2004-03-01 2011-07-06 テルモ株式会社 O−アルキル化ラパマイシン誘導体の製造法
EP1730525B1 (en) 2004-03-10 2013-06-19 Seradyn, Inc. Immunoassays for everolimus
AR047988A1 (es) * 2004-03-11 2006-03-15 Wyeth Corp Combinaciones antineoplásicas de cci-779 y rituximab
US8551512B2 (en) * 2004-03-22 2013-10-08 Advanced Cardiovascular Systems, Inc. Polyethylene glycol/poly(butylene terephthalate) copolymer coated devices including EVEROLIMUS
US8778014B1 (en) 2004-03-31 2014-07-15 Advanced Cardiovascular Systems, Inc. Coatings for preventing balloon damage to polymer coated stents
ATE410431T1 (de) * 2004-04-14 2008-10-15 Wyeth Corp Verfahren zur herstellung von rapamycin-42-estern und fk-506-32-estern mit dicarbonsäure, vorstufen für rapamycinkonjugate und antikörper
BRPI0510277A (pt) * 2004-04-27 2007-10-30 Wyeth Corp método para marcar especificamente uma rapamicina, rapamicina especificamente marcada, composição, e, kit
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
US8709469B2 (en) 2004-06-30 2014-04-29 Abbott Cardiovascular Systems Inc. Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device
GB0417852D0 (en) 2004-08-11 2004-09-15 Biotica Tech Ltd Production of polyketides and other natural products
EP1781672B1 (en) 2004-08-27 2010-10-06 Cordis Corporation Solvent free amorphous rapamycin
US8969379B2 (en) 2004-09-17 2015-03-03 Eisai R&D Management Co., Ltd. Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide
US7901451B2 (en) 2004-09-24 2011-03-08 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US8313763B2 (en) 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
AU2005294382A1 (en) * 2004-10-04 2006-04-20 Qlt Usa, Inc. Ocular delivery of polymeric delivery formulations
RU2007112787A (ru) * 2004-10-28 2008-12-10 Вайет (Us) ПРИМЕНЕНИЕ ИНГИБИТОРА mTOR ПРИ ЛЕЧЕНИИ ЛЕЙОМИОМЫ МАТКИ
US8021849B2 (en) 2004-11-05 2011-09-20 Siemens Healthcare Diagnostics Inc. Methods and kits for the determination of sirolimus in a sample
WO2006053754A1 (en) * 2004-11-19 2006-05-26 Novartis Ag COMBINATIONS OF ANTI-ATHEROSCLEROTIC PEPTIDES AND AN mTOR INHIBITING AGENT AND THEIR METHODS OF USE
US20060160837A1 (en) * 2004-12-29 2006-07-20 The Brigham And Women's Hospital, Inc. Rapamycin compounds in the treatment of neurofibromatosis type 1
US8637070B2 (en) 2005-02-09 2014-01-28 Santen Pharmaceutical Co., Ltd. Rapamycin formulations and methods of their use
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
GB0503936D0 (en) * 2005-02-25 2005-04-06 San Raffaele Centro Fond Method
GB0504544D0 (en) 2005-03-04 2005-04-13 Novartis Ag Organic compounds
US7241771B2 (en) 2005-03-07 2007-07-10 Wyeth Oxepane isomer of 42-O-(2-hydroxy)ethyl-rapamycin
GB0504994D0 (en) * 2005-03-11 2005-04-20 Biotica Tech Ltd Novel compounds
EP1896018A2 (en) 2005-03-11 2008-03-12 Biotica Technology Limited Medical uses of 39-desmethoxyrapamycin and analogues thereof
US20100061994A1 (en) * 2005-03-11 2010-03-11 Rose Mary Sheridan Medical uses of 39-desmethoxyrapamycin and analogues thereof
GT200600148A (es) * 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
US7189582B2 (en) 2005-04-27 2007-03-13 Dade Behring Inc. Compositions and methods for detection of sirolimus
EP3827747A1 (en) 2005-04-28 2021-06-02 Otsuka Pharmaceutical Co., Ltd. Pharma-informatics system
EP1890728A1 (en) * 2005-05-31 2008-02-27 Novartis AG Combination of hmg-coa reductase inhibitors amd mtor inhibitors
US20070004767A1 (en) * 2005-06-30 2007-01-04 Gutmann David H Methods for treating neurofibromatosis 1
WO2007011708A2 (en) 2005-07-15 2007-01-25 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
CA2615452C (en) 2005-07-15 2015-03-31 Micell Technologies, Inc. Polymer coatings containing drug powder of controlled morphology
EP1909794A2 (en) 2005-07-20 2008-04-16 Novartis AG Combination of organic compounds
RS54088B1 (en) 2005-07-25 2015-10-30 Emergent Products Development Seattle Llc B-CELL REDUCTION BY USING CD37-SPECIFIC AND CD20-SPECIFIC BINDING MOLECULES
EP1925676A4 (en) 2005-08-02 2010-11-10 Eisai R&D Man Co Ltd TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR
ES2611307T3 (es) 2005-08-30 2017-05-08 University Of Miami Inmunomodulación de agonistas, antagonistas e inmunotoxinas del receptor del factor de necrosis tumoral 25 (TNFR25)
EP1776970A1 (en) 2005-10-12 2007-04-25 Albert Schömig Implant with multiple coating
WO2007056118A1 (en) 2005-11-04 2007-05-18 Wyeth Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
GB0523659D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
KR20080077989A (ko) * 2005-12-20 2008-08-26 와이어쓰 약물의 불순물 조절을 통한 cci-779 제형의 안정성 조절
KR20080085213A (ko) * 2006-01-12 2008-09-23 노파르티스 아게 Mtor 억제제 및 항엽산 화합물의 조합물
US20070173923A1 (en) * 2006-01-20 2007-07-26 Savage Douglas R Drug reservoir stent
GB0601406D0 (en) * 2006-01-24 2006-03-08 Novartis Ag Organic Compounds
LT1983984T (lt) * 2006-02-02 2018-06-11 Novartis Ag Tuberozinės sklerozės gydymas
CA2635797C (en) 2006-02-09 2015-03-31 Macusight, Inc. Stable formulations, and methods of their preparation and use
US7622477B2 (en) * 2006-02-28 2009-11-24 Cordis Corporation Isomers and 42-epimers of rapamycin alkyl ether analogs, methods of making and using the same
US7678901B2 (en) 2006-02-28 2010-03-16 Wyeth Rapamycin analogs containing an antioxidant moiety
US7605257B2 (en) * 2006-03-07 2009-10-20 Wyeth Processes for preparing water-soluble polyethylene glycol conjugates of macrolide immunosuppressants
US8222271B2 (en) 2006-03-23 2012-07-17 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
CA2650590C (en) 2006-04-26 2018-04-03 Micell Technologies, Inc. Coatings containing multiple drugs
ES2556173T3 (es) 2006-05-18 2016-01-13 Eisai R&D Management Co., Ltd. Agente antitumoral para un cáncer de tiroides
GB0609963D0 (en) * 2006-05-19 2006-06-28 Biotica Tech Ltd Novel compounds
GB0609962D0 (en) * 2006-05-19 2006-06-28 Biotica Tech Ltd Novel compounds
WO2008053362A2 (en) * 2006-06-30 2008-05-08 Interface Biologics, Inc. Bioresponsive polymers
WO2008009079A2 (en) * 2006-07-20 2008-01-24 Gilead Sciences, Inc. Substituted pteridines useful for the treatment and prevention of viral infections
WO2008016633A2 (en) * 2006-08-02 2008-02-07 Ariad Gene Therapeutics, Inc. Combination therapy
US20080051691A1 (en) * 2006-08-28 2008-02-28 Wyeth Implantable shunt or catheter enabling gradual delivery of therapeutic agents
US8865737B2 (en) 2006-08-28 2014-10-21 Eisai R&D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
US8088789B2 (en) 2006-09-13 2012-01-03 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
US10695327B2 (en) 2006-09-13 2020-06-30 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
CN104906087A (zh) 2006-09-13 2015-09-16 万能医药公司 大环内酯化合物及它们的使用方法
EP2063905B1 (en) 2006-09-18 2014-07-30 Raptor Pharmaceutical Inc Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
US8067055B2 (en) * 2006-10-20 2011-11-29 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method of use
US20080097591A1 (en) 2006-10-20 2008-04-24 Biosensors International Group Drug-delivery endovascular stent and method of use
JP5456321B2 (ja) 2006-11-27 2014-03-26 テルモ株式会社 O−アルキル化ラパマイシン誘導体の製造方法およびo−アルキル化ラパマイシン誘導体
CN101711137B (zh) 2007-01-08 2014-10-22 米歇尔技术公司 具有可生物降解层的支架
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
CA2673991C (en) 2007-01-21 2012-02-07 Hemoteq Ag Methods for coating catheter balloons with a defined quantity of active agent
EP2119707B1 (en) 2007-01-29 2015-01-14 Eisai R&D Management Co., Ltd. Composition for treatment of undifferentiated-type of gastric cancer
TW200845960A (en) * 2007-04-05 2008-12-01 Wyeth Corp Wortmannin-rapalog conjugate and uses thereof
TW200901989A (en) 2007-04-10 2009-01-16 Wyeth Corp Anti-tumor activity of CCI-779 in papillary renal cell cancer
US9433516B2 (en) 2007-04-17 2016-09-06 Micell Technologies, Inc. Stents having controlled elution
US9192697B2 (en) 2007-07-03 2015-11-24 Hemoteq Ag Balloon catheter for treating stenosis of body passages and for preventing threatening restenosis
JP5599712B2 (ja) 2007-10-05 2014-10-01 インターフェース バイオロジクス,インコーポレーテッド オリゴフッ素化架橋ポリマーおよびそれの使用
US20110104228A1 (en) 2007-10-19 2011-05-05 Interface Biologics, Inc Self-eliminating coatings
CN101848895B (zh) 2007-11-09 2013-10-23 卫材R&D管理有限公司 血管新生抑制物质和抗肿瘤性铂络合物的组合使用
KR101587522B1 (ko) 2007-11-14 2016-01-21 바이오센서스 인터내셔널 그룹, 리미티드 자동화된 코팅장치 및 방법
WO2009089549A1 (en) 2008-01-11 2009-07-16 Massachusetts Eye & Ear Infirmary Conditional-stop dimerizable caspase transgenic animals
BRPI0822405A8 (pt) * 2008-03-11 2018-06-05 Elixir Medical Corp Método para tratar uma condição ou doença oftálmica, composição farmacêutica, dispositivo para o uso intracorporal, método para inibir a proliferação celular, composto, e, método para fabricar um composto
US20100048912A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
US8685995B2 (en) 2008-03-21 2014-04-01 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
NZ588671A (en) 2008-04-11 2012-11-30 Emergent Product Dev Seattle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
US20110098241A1 (en) * 2008-04-14 2011-04-28 Poniard Pharmaceuticals, Inc. Rapamycin analogs as anti-cancer agents
US9789233B2 (en) 2008-04-17 2017-10-17 Micell Technologies, Inc. Stents having bioabsorbable layers
US20110152380A1 (en) 2008-06-20 2011-06-23 Kovarik John M Paediatric Compositions For Treating Multiple Sclerosis
US8765162B2 (en) 2008-06-30 2014-07-01 Abbott Cardiovascular Systems Inc. Poly(amide) and poly(ester-amide) polymers and drug delivery particles and coatings containing same
CA2946195A1 (en) 2008-07-17 2010-01-21 Micell Technologies, Inc. Drug delivery medical device
WO2011009096A1 (en) 2009-07-16 2011-01-20 Micell Technologies, Inc. Drug delivery medical device
US8092822B2 (en) 2008-09-29 2012-01-10 Abbott Cardiovascular Systems Inc. Coatings including dexamethasone derivatives and analogs and olimus drugs
EP2352459A4 (en) * 2008-10-03 2013-09-25 Elixir Medical Corp MACROCYCLIC LACTONE COMPOUNDS AND METHODS OF USE
JP6265583B2 (ja) 2008-10-17 2018-01-24 ウィスコンシン アルムニ リサーチ ファンデイション 生理活性アルファベータペプチドを作製する方法
CN102292078A (zh) 2008-11-11 2011-12-21 得克萨斯大学体系董事会 哺乳动物雷帕霉素靶蛋白的抑制
TW201031675A (en) 2008-12-23 2010-09-01 Pharmasset Inc Synthesis of purine nucleosides
US8551973B2 (en) 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
AU2009329867B2 (en) 2008-12-23 2015-01-29 Gilead Pharmasset Llc Nucleoside phosphoramidates
EP2380006A4 (en) * 2009-01-21 2012-05-16 Biocon Ltd PROCESS FOR DETERMINING THE SIROLIMUS STABILITY AND METHOD FOR PRODUCING ITS STABLE FORM
EP2393827B1 (en) 2009-02-05 2015-10-07 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
WO2010103130A2 (en) 2009-03-13 2010-09-16 Katholieke Universiteit Leuven, K.U.Leuven R&D Novel bicyclic heterocycles
CA2757276C (en) 2009-04-01 2017-06-06 Micell Technologies, Inc. Coated stents
CN102481361B (zh) 2009-04-16 2014-10-22 默沙东公司 用于治疗癌症的组合物和方法
ES2942923T3 (es) 2009-05-06 2023-06-07 Laboratory Skin Care Inc Composiciones de administración dérmica que comprenden complejos de agente activo-partículas de fosfato de calcio y métodos de uso de las mismas
US10369256B2 (en) 2009-07-10 2019-08-06 Boston Scientific Scimed, Inc. Use of nanocrystals for drug delivery from a balloon
US10080821B2 (en) 2009-07-17 2018-09-25 Boston Scientific Scimed, Inc. Nucleation of drug delivery balloons to provide improved crystal size and density
JP2013501057A (ja) 2009-08-03 2013-01-10 ユニバーシティー・オブ・マイアミ 制御性t細胞のinvivoにおける増殖
AU2010310786B2 (en) 2009-10-23 2014-03-27 Eli Lilly And Company AKT inhibitors
WO2011053938A1 (en) 2009-10-30 2011-05-05 Ariad Pharmaceuticals, Inc. Methods and compositions for treating cancer
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
WO2015161139A1 (en) 2014-04-16 2015-10-22 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
NZ599964A (en) 2009-11-18 2014-08-29 Novartis Ag Methods and compositions for treating solid tumors and other malignancies
EP2513225A4 (en) 2009-12-18 2015-08-12 Interface Biologics Inc LOCAL ACTIVE INGREDIENT RELIEF FROM SELF-ORDINATED COATINGS
CN102127092B (zh) * 2010-01-18 2013-04-17 东南大学 依维莫斯的制备
WO2011097103A1 (en) 2010-02-02 2011-08-11 Micell Technologies, Inc. Stent and stent delivery system with improved deliverability
US20130195919A1 (en) 2010-03-05 2013-08-01 President And Fellows Of Harvard College Induced dendritic cell compositions and uses thereof
HUE026235T2 (en) 2010-03-31 2016-06-28 Gilead Pharmasset Llc Crystalline (S) -isopropyl 2 - (((S) - (((2R, 3R, 4R, 5R) -5- (2,4-dioxo-3,4-dihydropyrimidin-1 (2H) -IL) - 4-Fluoro-3-hydroxy-4-methyltetrahydrofuran-2-IL) methoxy) (phenoxy) phosphoryl) amino) propanoate
EP2558092B1 (en) 2010-04-13 2018-06-27 Novartis AG Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase 6 (cdk4/6) inhibitor and an mtor inhibitor for treating cancer
SG184311A1 (en) 2010-04-16 2012-11-29 Novartis Ag Combination of organic compounds
WO2011133655A1 (en) 2010-04-22 2011-10-27 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
EP2563391B1 (en) 2010-04-27 2020-08-26 Roche Glycart AG Combination therapy of an afucosylated cd20 antibody with a mtor inhibitor
GB201012889D0 (en) 2010-08-02 2010-09-15 Univ Leuven Kath Antiviral activity of novel bicyclic heterocycles
US9012458B2 (en) 2010-06-25 2015-04-21 Eisai R&D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
US20130172853A1 (en) 2010-07-16 2013-07-04 Micell Technologies, Inc. Drug delivery medical device
WO2012031236A1 (en) 2010-09-02 2012-03-08 Boston Scientific Scimed, Inc. Coating process for drug delivery balloons using heat-induced rewrap memory
GB201015411D0 (en) 2010-09-15 2010-10-27 Univ Leuven Kath Anti-cancer activity of novel bicyclic heterocycles
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
CN102464669B (zh) * 2010-11-17 2014-04-16 浙江海正药业股份有限公司 无定形依维莫司及其制备方法
WO2012066502A1 (en) * 2010-11-19 2012-05-24 Biocon Limited Processes for preparation of everolimus and intermediates thereof
WO2012103959A1 (en) 2011-02-04 2012-08-09 Synthon Bv Process for making everolimus
KR102024948B1 (ko) 2011-02-18 2019-11-04 노파르티스 파르마 아게 mTOR/JAK 저해제 병용 요법
CN102174053B (zh) * 2011-03-09 2014-04-16 成都雅途生物技术有限公司 依维莫司的纯化方法
CN106279401A (zh) 2011-03-11 2017-01-04 贝丝以色列女执事医疗中心 Cd40片段及其用途
EP2508525A1 (en) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
WO2012144463A1 (ja) 2011-04-18 2012-10-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
WO2012148846A1 (en) 2011-04-25 2012-11-01 Novartis Ag Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
WO2012166899A2 (en) 2011-06-03 2012-12-06 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
CA2838387A1 (en) 2011-06-06 2012-12-13 Chevron Phillips Chemical Company Lp Use of metallocene compounds for cancer treatment
EP2532740A1 (en) 2011-06-11 2012-12-12 Michael Schmück Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy
WO2013012689A1 (en) 2011-07-15 2013-01-24 Micell Technologies, Inc. Drug delivery medical device
WO2013013708A1 (en) 2011-07-26 2013-01-31 Fundació Institut D'investigació Biomèdica De Bellvitge Treatment of acute rejection in renal transplant
US20130028895A1 (en) 2011-07-27 2013-01-31 Gerald Wulf Exosome inhibiting agents and uses thereof
WO2013022458A1 (en) 2011-08-05 2013-02-14 Boston Scientific Scimed, Inc. Methods of converting amorphous drug substance into crystalline form
WO2013028208A1 (en) 2011-08-25 2013-02-28 Boston Scientific Scimed, Inc. Medical device with crystalline drug coating
CN102268015B (zh) * 2011-08-30 2013-08-28 成都摩尔生物医药有限公司 一种依维莫司的合成方法
GB201115665D0 (en) 2011-09-09 2011-10-26 Univ Leuven Kath Autoimmune and inflammatory disorder therapy
ES2663744T3 (es) 2011-10-06 2018-04-16 Novartis Ag Composiciones farmacéuticas que comprenden 40-O-(2-hidroxi)etil-rapamicina
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
EP2589383A1 (en) 2011-11-06 2013-05-08 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin FKBP subtype-specific rapamycin analogue for use in treatment of diseases
GB201122305D0 (en) 2011-12-23 2012-02-01 Biotica Tech Ltd Novel compound
CA2868392A1 (en) 2012-05-23 2013-11-28 Estelle DOUDEMENT Compositions and methods of obtaining and using endoderm and hepatocyte cells
CN102786534A (zh) * 2012-05-25 2012-11-21 上海现代制药股份有限公司 一种依维莫司的制备方法
PL2859001T3 (pl) 2012-06-08 2016-08-31 Biotronik Ag 40-o-podstawiona pochodna estrowa rapamycyny i węglowodoru cyklicznego, kompozycje i metody
WO2013192367A1 (en) 2012-06-22 2013-12-27 Novartis Ag Neuroendocrine tumor treatment
CN103705925B (zh) 2012-09-29 2018-03-30 段磊 抑制PI3K/AKT/mTOR信号通路的药物组合
US9750728B2 (en) 2012-09-29 2017-09-05 Targeted Therapeutics, Llc Method and pharmaceutical composition for inhibiting PI3K/AKT/mTOR signaling pathway
WO2014059295A1 (en) 2012-10-12 2014-04-17 The Board Of Regents Of The University Of Texas System Use of mtor inhibitors to treat vascular cognitive impairment
EP2914260A1 (en) 2012-10-31 2015-09-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preventing antiphospholipid syndrome (aps)
EP2919759A4 (en) 2012-11-14 2016-07-20 Ohio State Innovation Foundation MATERIALS AND METHODS FOR THE TREATMENT OF GLIOBLASTOMES
JP2016500112A (ja) * 2012-11-30 2016-01-07 ハンジョウ ジロックス ファーマ カンパニー リミテッドHangzhou Zylox Pharma Co.,Ltd. ラパマイシン類似体及びその製作方法
KR20150098605A (ko) 2012-12-21 2015-08-28 에자이 알앤드디 매니지먼트 가부시키가이샤 퀴놀린 유도체의 비정질 형태 및 그의 제조방법
WO2014110258A1 (en) 2013-01-09 2014-07-17 Podack Eckhard R Compositions and methods for the regulation of t regulatory cells using tl1a-ig fusion protein
JP6330024B2 (ja) 2013-03-12 2018-05-23 マイセル・テクノロジーズ,インコーポレイテッド 生体吸収性バイオメディカルインプラント
WO2014160328A1 (en) 2013-03-13 2014-10-02 The Board Of Regents Of The University Of Texas System Mtor inhibitors for prevention of intestinal polyp growth
KR20150127720A (ko) 2013-03-14 2015-11-17 유니버시티 오브 매릴랜드, 발티모어 안드로겐 수용체 하향 조절제 및 그의 용도
US10098871B2 (en) 2013-03-15 2018-10-16 Leslie B. Gordon Combination therapies for treatment of laminopathies, cellular aging, and atherosclerosis
TW201503912A (zh) 2013-03-19 2015-02-01 Novartis Ag 包含癌莫事(everolimus)之醫藥組合物
WO2014182635A1 (en) 2013-05-08 2014-11-13 Baldwin Megan E Biomarkers for age-related macular degeneration (amd)
KR102204279B1 (ko) 2013-05-14 2021-01-15 에자이 알앤드디 매니지먼트 가부시키가이샤 자궁내막암 대상의 렌바티닙 화합물에 대한 반응성을 예측 및 평가하기 위한 생체표지
US10272606B2 (en) 2013-05-15 2019-04-30 Micell Technologies, Inc. Bioabsorbable biomedical implants
WO2014200659A1 (en) 2013-06-11 2014-12-18 Clontech Laboratories, Inc. Protein enriched microvesicles and methods of making and using the same
US20160130280A1 (en) * 2013-06-20 2016-05-12 Novartis Ag Alkylation with an alkyl fluoroalkyl sulfonate
CN103360411B (zh) * 2013-07-17 2015-09-30 成都雅途生物技术有限公司 依维莫司结晶提纯方法
BR112016002970A2 (pt) 2013-08-12 2017-09-12 Tokai Pharmaceuticals Inc biomarcadores para o tratamento de distúrbios neoplásicos que usa terapias direcionadas ao androgênio
US9580758B2 (en) 2013-11-12 2017-02-28 Luc Montagnier System and method for the detection and treatment of infection by a microbial agent associated with HIV infection
EP3068435A1 (en) 2013-11-13 2016-09-21 Novartis AG Mtor inhibitors for enhancing the immune response
RU2714902C2 (ru) 2013-12-19 2020-02-20 Новартис Аг Химерные рецепторы антигена против мезотелина человека и их применение
JP6793902B2 (ja) 2013-12-20 2020-12-02 ノバルティス アーゲー 調節可能キメラ抗原受容体
KR101529963B1 (ko) * 2013-12-27 2015-06-19 주식회사 종근당바이오 에베로리무스의 제조방법 및 이의 중간체
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
CA3206208A1 (en) 2013-12-31 2015-07-09 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use
EP3094314B1 (en) 2014-01-16 2021-06-23 MUSC Foundation For Research Development Targeted nanocarriers for the administration of immunosuppressive agents
KR20160110963A (ko) 2014-02-11 2016-09-23 노파르티스 아게 암 치료를 위한 pi3k 억제제를 포함하는 제약 조합물
WO2015142661A1 (en) 2014-03-15 2015-09-24 Novartis Ag Regulatable chimeric antigen receptor
EP3593812A3 (en) 2014-03-15 2020-05-27 Novartis AG Treatment of cancer using chimeric antigen receptor
CN103848849B (zh) * 2014-03-24 2016-02-24 上海医药工业研究院 依维莫司的制备工艺
CA2943609A1 (en) 2014-03-27 2015-10-01 The Brigham And Women's Hospital, Inc. Metabolically-activated drug conjugates to overcome resistance in cancer therapy
KR20240042250A (ko) 2014-04-07 2024-04-01 노파르티스 아게 항-cd19 키메라 항원 수용체를 사용한 암의 치료
US10258639B2 (en) 2014-05-06 2019-04-16 Research Development Foundation Methods for treating insulin resistance and for sensitizing patients to GLP1 agonist therapy
CN105254646A (zh) * 2014-05-28 2016-01-20 上海博邦医药科技有限公司 一种制备依维莫司的方法
CA2950589A1 (en) 2014-06-02 2015-12-10 Children's Medical Center Corporation Methods and compositions for immunomodulation
MX2017001011A (es) 2014-07-21 2018-05-28 Novartis Ag Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma.
CN107109419B (zh) 2014-07-21 2020-12-22 诺华股份有限公司 使用cd33嵌合抗原受体治疗癌症
JP2017528433A (ja) 2014-07-21 2017-09-28 ノバルティス アーゲー 低い免疫増強用量のmTOR阻害剤とCARの組み合わせ
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
US20170209492A1 (en) 2014-07-31 2017-07-27 Novartis Ag Subset-optimized chimeric antigen receptor-containing t-cells
WO2016020664A1 (en) * 2014-08-04 2016-02-11 Cipla Limited Process for the synthesis of everolimus and intermediates thereof
CN117088931A (zh) 2014-08-12 2023-11-21 莫纳什大学 定向淋巴的前药
WO2016025880A1 (en) 2014-08-14 2016-02-18 Novartis Ag Treatment of cancer using gfr alpha-4 chimeric antigen receptor
SG11201700770PA (en) 2014-08-19 2017-03-30 Novartis Ag Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
RS63559B1 (sr) 2014-08-28 2022-10-31 Eisai R&D Man Co Ltd Derivat hinolina velike čistoće i postupak za njegovu proizvodnju
EP3193902A4 (en) 2014-09-11 2018-03-28 The Regents of The University of California mTORC1 INHIBITORS
US10577417B2 (en) 2014-09-17 2020-03-03 Novartis Ag Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
JP6815992B2 (ja) 2014-10-08 2021-01-20 ノバルティス アーゲー キメラ抗原受容体療法に対する治療応答性を予測するバイオマーカーおよびその使用
WO2016068208A1 (ja) 2014-10-28 2016-05-06 国立研究開発法人国立成育医療研究センター 妊娠状態を改善するための薬剤及びその利用
WO2016066608A1 (en) 2014-10-28 2016-05-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of pulmonary cell senescence and peripheral aging
EP3473253A1 (en) 2014-10-29 2019-04-24 University Of Maryland Methods of treating age-related symptoms in mammals and compositions therefor
CN104478898A (zh) * 2014-11-18 2015-04-01 连云港恒运医药科技有限公司 依维莫司及其中间体的制备方法
WO2016135740A1 (en) 2015-02-23 2016-09-01 Natco Pharma Limited Process for preparing stable oral compositions of everolimus
PL3263106T3 (pl) 2015-02-25 2024-04-02 Eisai R&D Management Co., Ltd. Sposób tłumienia goryczy pochodnej chinoliny
MD20170081A2 (ro) 2015-03-04 2018-03-31 Gilead Sciences, Inc. Compuşi 4,6-diamino-pirido[3,2-D]pirimidină modulatori ai receptorilor de tip Toll
AU2015384801B2 (en) 2015-03-04 2022-01-06 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
US11896614B2 (en) 2015-04-17 2024-02-13 Novartis Ag Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
EP3286211A1 (en) 2015-04-23 2018-02-28 Novartis AG Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
AU2016263176A1 (en) 2015-05-20 2017-12-07 Novartis Ag Pharmaceutical combination of everolimus with dactolisib
CN104892632B (zh) * 2015-06-03 2017-12-26 道中道(菏泽)制药有限公司 一种晶体形式的依维莫司及其制备方法
BR112017027227B1 (pt) 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd Agente anti-câncer
EP3109250A1 (en) 2015-06-23 2016-12-28 Synbias Pharma AG Method for the synthesis of rapamycin derivatives
WO2017029391A1 (en) 2015-08-20 2017-02-23 INSERM (Institut National de la Santé et de la Recherche Médicale) New method for treating cancer
AU2016315873B2 (en) 2015-09-04 2022-08-18 Primatope Therapeutics Inc. Humanized anti-CD40 antibodies and uses thereof
WO2017041139A1 (en) 2015-09-08 2017-03-16 Monash University Lymph directing prodrugs
AU2016352806A1 (en) 2015-11-11 2018-05-10 Novartis Ag Uses of myostatin antagonists, combinations containing them and uses thereof
CN105566348A (zh) * 2015-12-31 2016-05-11 哈药集团技术中心 一种依维莫司的制备方法
CN116077439A (zh) * 2016-04-29 2023-05-09 西奈山伊坎医学院 靶向先天免疫系统以诱导长期耐受性及解决动脉粥样硬化中的巨噬细胞累积
US20190290631A1 (en) 2016-05-27 2019-09-26 Nippon Kayaku Kabushiki Kaisha Pharmaceutical composition comprising rapamycin or derivative thereof
CA3031542A1 (en) 2016-07-20 2018-01-25 University Of Utah Research Foundation Cd229 car t cells and methods of use thereof
CA3035346A1 (en) 2016-09-02 2018-03-08 Gilead Sciences, Inc. Toll like receptor modulator compounds
US10640499B2 (en) 2016-09-02 2020-05-05 Gilead Sciences, Inc. Toll like receptor modulator compounds
CN117866991A (zh) 2016-10-07 2024-04-12 诺华股份有限公司 用于治疗癌症的嵌合抗原受体
WO2018096402A1 (en) 2016-11-23 2018-05-31 Novartis Ag Methods of enhancing immune response with everolimus, dactolisib or both
EP3548894B1 (en) 2016-12-02 2021-10-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for diagnosing renal cell carcinoma
HUE056777T2 (hu) 2016-12-22 2022-03-28 Amgen Inc Benzizotiazol-, izotiazolo[3,4-b]piridin-, kinazolin-, ftálazin-, pirido[2,3-d]piridazin- és pirido[2,3-d]pirimidin-származékok mint KRAS G12C inhibitorok tüdõ-, hasnyálmirigy- vagy vastagbélrák kezelésére
GB201701087D0 (en) 2017-01-23 2017-03-08 Univ Leuven Kath Novel prodrugs of mizoribine
JP2020507632A (ja) 2017-02-10 2020-03-12 マウント タム セラピューティクス, インコーポレイテッドMount Tam Therapeutics, Inc. ラパマイシン類似体
EP3615055A1 (en) 2017-04-28 2020-03-04 Novartis AG Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
ES2871499T3 (es) 2017-05-15 2021-10-29 Bard Inc C R Dispositivo médico con recubrimiento de elución de fármaco y capa intermedia
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
EP3644997A1 (en) 2017-06-26 2020-05-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of olmsted syndrome
WO2019012024A1 (en) 2017-07-13 2019-01-17 INSERM (Institut National de la Santé et de la Recherche Médicale) METHODS FOR INCREASING EXPANSION AND IMMUNOSUPPRESSIVE CAPACITY OF A CD8 + CD45RCBAS TREGS POPULATION / -
US11883497B2 (en) 2017-08-29 2024-01-30 Puretech Lyt, Inc. Lymphatic system-directing lipid prodrugs
JP7150823B2 (ja) 2017-09-08 2022-10-11 アムジエン・インコーポレーテツド KRas G12Cの阻害剤及びそれを使用する方法
AR112834A1 (es) 2017-09-26 2019-12-18 Novartis Ag Derivados de rapamicina
CN108047265A (zh) * 2017-11-24 2018-05-18 成都海创药业有限公司 一种依维莫司中间体的制备纯化方法
US11608345B1 (en) 2017-12-19 2023-03-21 Puretech Lyt, Inc. Lipid prodrugs of rapamycin and its analogs and uses thereof
US11304954B2 (en) 2017-12-19 2022-04-19 Puretech Lyt, Inc. Lipid prodrugs of mycophenolic acid and uses thereof
WO2019157516A1 (en) 2018-02-12 2019-08-15 resTORbio, Inc. Combination therapies
US20210047405A1 (en) 2018-04-27 2021-02-18 Novartis Ag Car t cell therapies with enhanced efficacy
CR20200578A (es) 2018-05-01 2021-02-22 Revolution Medicines Inc Análogos de rapamicina a c40, c28 y c32 como inhibidores de mtor
WO2019213282A1 (en) 2018-05-01 2019-11-07 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
CN112368289B (zh) 2018-05-01 2024-02-20 锐新医药公司 作为mtor抑制剂的c26-连接的雷帕霉素类似物
JP7361722B2 (ja) 2018-05-04 2023-10-16 アムジエン・インコーポレーテツド Kras g12c阻害剤及び同一物の使用方法
US11090304B2 (en) 2018-05-04 2021-08-17 Amgen Inc. KRAS G12C inhibitors and methods of using the same
EP3790886A1 (en) 2018-05-10 2021-03-17 Amgen Inc. Kras g12c inhibitors for the treatment of cancer
WO2019222843A1 (en) 2018-05-22 2019-11-28 Interface Biologics, Inc. Compositions and methods for delivering drugs to a vessel wall
AR126019A1 (es) 2018-05-30 2023-09-06 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
WO2019232419A1 (en) 2018-06-01 2019-12-05 Amgen Inc. Kras g12c inhibitors and methods of using the same
CA3099799A1 (en) 2018-06-11 2019-12-19 Amgen Inc. Kras g12c inhibitors for treating cancer
AU2019336588B2 (en) 2018-06-12 2022-07-28 Amgen Inc. KRAS G12C inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer
CN112203725A (zh) 2018-06-13 2021-01-08 诺华股份有限公司 Bcma嵌合抗原受体及其用途
CN108676014A (zh) * 2018-06-15 2018-10-19 国药集团川抗制药有限公司 纯化依维莫司中间体的方法以及制备依维莫司的方法
EP3826650A4 (en) 2018-07-23 2022-07-27 Enclear Therapies, Inc. METHODS OF TREATMENT OF NEUROLOGICAL DISEASES
JP2022510573A (ja) 2018-07-23 2022-01-27 エンクリアー セラピーズ, インク. 神経障害の治療方法
US20220047567A1 (en) 2018-09-10 2022-02-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of neurofibromatosis
CN113167798A (zh) 2018-10-05 2021-07-23 卫材R&D管理有限公司 用于包含乐伐替尼和依维莫司的组合疗法的生物标志物
EP3880266A1 (en) 2018-11-14 2021-09-22 Lutonix, Inc. Medical device with drug-eluting coating on modified device surface
JP2020090482A (ja) 2018-11-16 2020-06-11 アムジエン・インコーポレーテツド Kras g12c阻害剤化合物の重要な中間体の改良合成法
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
CA3117222A1 (en) 2018-11-19 2020-05-28 Amgen Inc. Kras g12c inhibitors and methods of using the same
EP3897852A1 (en) 2018-12-20 2021-10-27 Amgen Inc. Kif18a inhibitors
EP3897855B1 (en) 2018-12-20 2023-06-07 Amgen Inc. Kif18a inhibitors
EP3898616A1 (en) 2018-12-20 2021-10-27 Amgen Inc. Heteroaryl amides useful as kif18a inhibitors
WO2020132653A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Heteroaryl amides useful as kif18a inhibitors
US20220040324A1 (en) 2018-12-21 2022-02-10 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor
WO2020154447A1 (en) * 2019-01-22 2020-07-30 Aeovian Pharmaceuticals, Inc. Mtorc modulators and uses thereof
MX2021010319A (es) 2019-03-01 2021-12-10 Revolution Medicines Inc Compuestos biciclicos de heteroarilo y usos de estos.
CA3130083A1 (en) 2019-03-01 2020-09-10 Revolution Medicines, Inc. Bicyclic heterocyclyl compounds and uses thereof
WO2020209828A1 (en) 2019-04-08 2020-10-15 Bard Peripheral Vascular, Inc. Medical device with drug-eluting coating on modified device surface
AU2020271894A1 (en) 2019-04-11 2021-12-02 Enclear Therapies, Inc. Methods of amelioration of cerebrospinal fluid and devices and systems therefor
TWI751516B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
EP3738593A1 (en) 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
SG11202112855WA (en) 2019-05-21 2021-12-30 Amgen Inc Solid state forms
TW202115056A (zh) 2019-06-28 2021-04-16 美商基利科學股份有限公司 類鐸受體調節劑化合物的製備方法
WO2021001743A1 (en) 2019-07-02 2021-01-07 Effector Therapeutics, Inc. Translation inhibitors and uses thereof
WO2021026101A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
WO2021026098A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
AU2020325115A1 (en) 2019-08-02 2022-03-17 Amgen Inc. Pyridine derivatives as KIF18A inhibitors
CA3147272A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
WO2021055728A1 (en) 2019-09-18 2021-03-25 Merck Sharp & Dohme Corp. Small molecule inhibitors of kras g12c mutant
EP4031578A1 (en) 2019-09-18 2022-07-27 Novartis AG Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
CA3155857A1 (en) 2019-10-24 2021-04-29 Amgen Inc. PYRIDOPYRIMIDINE DERIVATIVES USEFUL AS KRAS G12C AND KRAS G12D INHIBITORS IN THE TREATMENT OF CANCER
EP4051678A1 (en) 2019-10-28 2022-09-07 Merck Sharp & Dohme Corp. Small molecule inhibitors of kras g12c mutant
EP4051266A1 (en) 2019-10-31 2022-09-07 Taiho Pharmaceutical Co., Ltd. 4-aminobut-2-enamide derivatives and salts thereof
AU2020379731A1 (en) 2019-11-04 2022-05-05 Revolution Medicines, Inc. Ras inhibitors
EP4055028A1 (en) 2019-11-04 2022-09-14 Revolution Medicines, Inc. Ras inhibitors
MX2022005359A (es) 2019-11-04 2022-06-02 Revolution Medicines Inc Inhibidores de ras.
CN114901662A (zh) 2019-11-08 2022-08-12 锐新医药公司 双环杂芳基化合物及其用途
US20230192682A1 (en) 2019-11-14 2023-06-22 Amgen Inc. Improved synthesis of kras g12c inhibitor compound
AU2020381492A1 (en) 2019-11-14 2022-05-26 Amgen Inc. Improved synthesis of KRAS G12C inhibitor compound
WO2021108683A1 (en) 2019-11-27 2021-06-03 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
WO2021106231A1 (en) 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
JP2023509701A (ja) 2020-01-07 2023-03-09 レヴォリューション・メディスンズ,インコーポレイテッド Shp2阻害剤投薬およびがんを処置する方法
CA3166908A1 (en) 2020-02-05 2021-08-12 Daniel Kenneth BONNER Lipid prodrugs of neurosteroids
WO2021215545A1 (en) 2020-04-24 2021-10-28 Taiho Pharmaceutical Co., Ltd. Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c
EP4139299A1 (en) 2020-04-24 2023-03-01 Taiho Pharmaceutical Co., Ltd. Kras g12d protein inhibitors
KR20230031926A (ko) 2020-07-15 2023-03-07 다이호야쿠힌고교 가부시키가이샤 종양의 치료에 사용되는 피리미딘 화합물을 포함하는 조합
AU2021344830A1 (en) 2020-09-03 2023-04-06 Revolution Medicines, Inc. Use of SOS1 inhibitors to treat malignancies with SHP2 mutations
KR20230067635A (ko) 2020-09-15 2023-05-16 레볼루션 메디슨즈, 인크. 암의 치료에서 ras 억제제로서 인돌 유도체
JP2024501280A (ja) 2020-12-22 2024-01-11 キル・レガー・セラピューティクス・インコーポレーテッド Sos1阻害剤およびその使用
CN117355298A (zh) 2021-03-19 2024-01-05 生物治疗探索股份有限公司 用于调节训练免疫的化合物及其使用方法
EP4334324A1 (en) 2021-05-05 2024-03-13 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
WO2022235864A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Ras inhibitors
WO2022235870A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Ras inhibitors for the treatment of cancer
CN117769554A (zh) 2021-05-28 2024-03-26 大鹏药品工业株式会社 Kras突变蛋白的小分子抑制剂
CA3223081A1 (en) 2021-07-15 2023-01-19 Samir Mitragotri Compositions and methods relating to cells with adhered particles
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
WO2023114954A1 (en) 2021-12-17 2023-06-22 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2024008799A1 (en) 2022-07-06 2024-01-11 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of proliferative glomerulonephritis
WO2024028433A1 (en) 2022-08-04 2024-02-08 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of lymphoproliferative disorders
WO2024081916A1 (en) 2022-10-14 2024-04-18 Black Diamond Therapeutics, Inc. Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
WO2024100236A1 (en) 2022-11-11 2024-05-16 Astrazeneca Ab Combination therapies for the treatment of cancer
CN116813641A (zh) * 2023-06-09 2023-09-29 杭州华东医药集团康润制药有限公司 一种依维莫司的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5540931A (en) * 1989-03-03 1996-07-30 Charles W. Hewitt Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
US5120842A (en) * 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5151413A (en) * 1991-11-06 1992-09-29 American Home Products Corporation Rapamycin acetals as immunosuppressant and antifungal agents
US5302584A (en) * 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
US5258389A (en) * 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
US5310903A (en) * 1993-03-05 1994-05-10 Merck & Co., Inc. Imidazolidyl rapamycin derivatives
US5378836A (en) * 1993-10-08 1995-01-03 American Home Products Corporation Rapamycin oximes and hydrazones
US5527907A (en) * 1993-11-19 1996-06-18 Abbott Laboratories Macrolide immunomodulators
CN1046944C (zh) * 1993-12-17 1999-12-01 山道士有限公司 雷怕霉素类衍生物

Also Published As

Publication number Publication date
HU224074B1 (hu) 2005-05-30
ES2225919T3 (es) 2005-03-16
FI20001943A (fi) 2000-09-04
DE122004000033I2 (de) 2006-12-21
FI951678A (fi) 1995-04-07
RO114451B1 (ro) 1999-04-30
CY2005010I1 (el) 2010-07-28
CY2005010I2 (el) 2016-10-05
CA2476257A1 (en) 1994-04-28
DK0663916T3 (da) 1999-08-09
DE69333577T2 (de) 2005-07-21
NO951312L (no) 1995-06-08
NO951312D0 (no) 1995-04-05
DE122004000033I1 (de) 2006-11-16
EP0663916A1 (en) 1995-07-26
PT867438E (pt) 2004-11-30
RU95110053A (ru) 1997-03-20
EP0867438B1 (en) 2004-07-28
DK0867438T3 (da) 2004-12-06
KR950703567A (ko) 1995-09-20
HU9501016D0 (en) 1995-06-28
ATE272063T1 (de) 2004-08-15
NL300154I1 (nl) 2004-09-01
KR100307831B1 (ko) 2001-09-24
KR100308598B1 (ko) 2001-11-30
DE69322282T2 (de) 1999-05-12
EP0867438A1 (en) 1998-09-30
JPH11240884A (ja) 1999-09-07
SK46595A3 (en) 1995-08-09
NO2017067I2 (no) 2017-12-07
AU4819293A (en) 1994-05-09
DE69322282D1 (de) 1999-01-07
FR04C0012I1 (sk) 2004-09-17
NO2004001I2 (no) 2006-04-10
HUT71232A (en) 1995-11-28
NZ256026A (en) 1996-08-27
DE69333577D1 (de) 2004-09-02
JP3117462B2 (ja) 2000-12-11
FI951678A0 (fi) 1995-04-07
RU2143434C1 (ru) 1999-12-27
WO1994009010A1 (en) 1994-04-28
SK285256B6 (sk) 2006-10-05
EP1413581A1 (en) 2004-04-28
CY2125B1 (en) 2002-06-21
ES2124793T3 (es) 1999-02-16
US5665772A (en) 1997-09-09
LU91104I2 (fr) 2004-11-29
ATE173736T1 (de) 1998-12-15
GB9221220D0 (en) 1992-11-25
FR04C0012I2 (fr) 2005-02-11
CZ89995A3 (en) 1995-09-13
CA2476257C (en) 2009-11-10
PL176174B1 (pl) 1999-04-30
SK286054B6 (sk) 2008-02-05
JP3568800B2 (ja) 2004-09-22
NO2017067I1 (no) 2017-12-07
BR1100353A (pt) 2000-06-06
JPH08502266A (ja) 1996-03-12
NL300154I2 (nl) 2004-10-01
CA2145383C (en) 2004-11-16
NO307053B1 (no) 2000-01-31
GEP20002331B (en) 2000-12-25
CA2145383A1 (en) 1994-04-28
CZ283333B6 (cs) 1998-02-18
PL308268A1 (en) 1995-07-24
EP0663916B1 (en) 1998-11-25
AU676198B2 (en) 1997-03-06
US6440990B1 (en) 2002-08-27

Similar Documents

Publication Publication Date Title
FI109540B (fi) Menetelmä terapeuttisesti käyttökelpoisen 40-0-(2-hydroksietyyli) -rapamysiinin valmistamiseksi
EP0734389B1 (en) Rapamycin derivatives useful as immunosuppressants
US5985890A (en) Rapamycin derivatives
CA2174731C (en) Rapamycin derivatives useful as immunosuppressants

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: NOVARTIS AG

SPCF Supplementary protection certificate application filed

Spc suppl protection certif: L20040004

MA Patent expired
SPCE Application for extension of a supplementary protection certificate [pediatric extension]

Spc suppl protection certif: L20040004

SPCP Extension of a supplementary protection certificate [pediatric extension]

Spc suppl protection certif: 240

Extension date: 20190118